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During routine drug analysis with the Syva d.a.u. Emit immunoassays we observed a high frequency of urines with lower rates of changes in absorbance (iSA A) than the rate for a drug-free urine calibrator. Many of these urines contained salicylates.
Among 40 urines with apparent salicylate concentrations between 15 and 420 mg/dL tested for benzoylecgonine (BE) , 20 had #{163}4 R <-4 (range +2 to -28 mA/mm). The rates decreased with increasing salicylate: #{163}4 A = -0.057 x (salicylate, mg/ dL) -0.22 m/Vmin (r = 0.85, n = 40, P <0.01). Urines from 100 control subjects (no salicylate) had mean ± SD #{163}4 R values of -1.05 ± 2.2 m/Vmin (range +3 to -7; only two were <-4 mkmin). Although direct addition of salicylic acid (200 mg/dL) to urine specimens did not reproduce the negative bias, ingestion of aspirin (acetylsalicylic acid) did by -0.09 mA were mixed with the Syva high calibrator (containing BE) to yield samples with various concentrations of BE. We analyzed these samples with the cocaine Emit d.a.u. assay and plotted the standard concentration-response curves as BE concentration vs the delta absqrbance rate, #{163}4 R (mA/mm of sample minus mA/mm of the negative calibrator).
To test the potential inhibition by salicylate-containing urines of the enzyme glucose-6-phosphate dehydrogenase (EC 1.1.1.49) used in the Emit reagents, we concentrated a urine specimen containing 84 mg/dL of excreted salicylate (Trinder method) and a urine specimen from the same individual collected before the ingestion of aspirin. We used a Speed-vac (Savant Instruments, Farmingdale, NY) to concentrate both urines to the same extent; the final salicylate concentration in the salicylate-containing urine was 672 mg/dL. The reagents (Ri and R2) from two different Emit drug kits (amphetamine and BE) were interchanged to maintain the chemical integrity of the reagent mixtures. After diluting the concentrated salicylate-containing urine with the salicylate-free concentrated urine, we assayed the resulting samples by using Ri for amphetamine and R2 for BE and then using Ri for BE and R2 for amphetamine. This was done to test the inhibition of the enzyme after accounting for any effects of antibody and (or) drug concentration.
Reagent Ri contains glucose 6-phosphate, NAD, antibody, and stabilizing agents; reagent R2 contains glucose-6-phosphate dehydrogenase covalently attached to the specific drug and stabilizing agents (Syva package insert). In the absence of the appropriate antibody, the assay should proceed at maximal velocity; a decrease in the observed rate should be attributable to inhibitor(s) present in the urine sample.
Results
Reduced delta absorbance rates in Emit cocaine assay. Fig. 1 shows the relationship between salicylate concentration in urine and reduced delta absorbance rate (A R) measured with the Emit cocaine assay in 40 saucylate-containing urine specimens. Twenty (50%) of these samples gave negative absorbance rates <-4 mAimin (range -6 to -28 mA/mm).
In contrast, the mean #{163}4 R for a series of 100 control subjects (not taking drugs or salicylates) requiring drug screening in our Emergency Department was -1.05 mA/mm (range +3 to -7 mA! mm, SD = 2.18, SE = 0.22). Only two of the controls had rates <-4 mAjmin.
Recovery experiments with BE and salicylate.
To determine the magnitude of negative bias in the measured concentration of BE caused by various amounts of salicylate in urine, we added BE concentrations of 300, 600, and 900 ng/mL to two control urines (not containing salicylates) and to 16 urines (salicylate concentrations 15-420 mg/dL) from salicylate-positive subjects submitted for routine drug screening. This established a fourpoint standard calibration curve for each of these 18 urines, from which we wanted to determine how much BE was needed to exceed the #{163}4 R of the 300 ng/mL calibrator.
Fifteen (94%) of the 16 urines containing salicylates required >300 ngfmL of BE before they produced a positive screening result by this assay. Effects of urine salicylates on enzyme activity. To determine whether the bias was due to influences on the antibody component or the reaction indicator component of the Emit reagents, we exchanged reagents from two different Emit assays to eliminate the effects of antibody binding to the enzyme. The matrix of the concentrated urine was held constant and thus compared with itself but containing no salicylate. Fig. 4 shows that increasing the concentrations of measured salicylate in urine from one individual proportionately reduced the apparent enzymatic activity of the glucose-6-phosphate dehydrogenase.
Under these experimental conditions a decrease in the observed enzymatic rate would be due to inhibition of the enzyme or inhibition of the apparent rate of the reaction by substances present in the urine sample. The results demonstrate that the bias is not an antibody-related phenomenon and suggest that the interference acts by reducing the signal of the indicator reaction. 
Effects of urine salicyl ate on other Emit assays. Using seven additional
Emit d.a.u. assays-amphetamines, barbiturates, opiates, benzodia.zapines, phencycidine, propoxyphene, and tetrahydrocannabinol-we measured four urine specimens with salicylate contents ranging from 0 to 100 mg/dL obtained from one of the volunteers who ingested aspirin. Reduced signals (mA/ miii) were observed in all cases, paralleling the increased salicylate concentrations in the urine specimens (data not shown).
Discussion
Apparently, ingestion of therapeutic doses of acetylsalicylic acid causes a reduction in the signal of the Emit d.a.u. assays with urine samples. Although direct addition of salicylic acid to urine did not produce the negative bias, ingestion of aspirin did. Our data suggest that either metabolic products of acetylsalicylic acid produce the decreased signal in urine, or ingestion of aspirin induces excretion of some other substance(s) whose presence similarly affects the Emit methodology.
The hypothesis implicating the metabolism of salicylate is the simplest explanation.
Aspirin is converted to acetic acid and salicylic acid in the stomach. A major portion is also metabolized by microbial esterases in gut and by esterases in blood and liver. Salicylates are excreted in urine as various conjugated species (11, 12): free salicylic acid (10%), salicyluric acid (75%), salicylic phenolic (10%) and acyl (5%) glucuronides, and gentisic acid (<1%). The excretion of free salicylate is variable and depends on both the dose ingested and the urinary pH. In alkaline urine, >30% of the ingested aspirin may be excreted as free salicylate, whereas in acidic urine this may be as low as 2% (for more detail see 11, 12).
The extent to which metabolic products of salicylates are measured by the Trinder method is not well defined. The scatter in the correlations plots between measured salicylates and magnitude of decreased signal for different subjects (Fig. 1) and apparent salicylate concentration seen in urine from one subject (Fig. 4) 
(12).
This leads to the second point, the amount of aspirin ingestion required to induce the bias observed in our studies. Ingestion of four 325-mg tablets of aspirin was easily tolerated by our subjects. The magnitude of peak salicylate concentrations in urine and the time to reach the peak varied considerably between subjects ingesting aspirin (Fig. 3) . According to medical texts (13), daily doses of up to 3 to 7.5 g of aspirin per day (about 10 to 25 325-mg tablets) are prescribed for patients being treated for rheumatoid arthritis. Salicylate concentrations would be considerably higher in urine than in serum depending on (e.g.) the time of urine collection and the state of hydration of subject. Thus, concentrations of salicylate metabolites in urine greater than those tested in this study can be easily achieved.
The third consideration is the extent to which the observed bias in the absorbance rate creates problems in screening. This depends largely on three variables: the reproducibility of assay response for subjects not taking cocaine; the distribution of mA/min values for the population of individuals screened who are using cocaine; and the apparent salicylate concentrations achievable in urine. The mean #{163}4. R in our Emit cocaine d.a.u. assay was -1.05 mA/mn (range +3 to -7, SD = 2.18, SE = 0.21) for 100 subjects (drug-free, including no salicylates) who presented to our Emergency Department requiring drug screens (Fig. 1) . Thus, in our hands, the mAImin variability in urines from these subjects is well within the limit of ± 5 mA/mm variation as a routine quality-control criterion. Fig. 1 shows that apparent salicylate values as low as 50 mg/dL may shift the baseline to <-5 mA/mm. Thus, the probabifity of obtaining a false-negative result will depend on the actual concentrations of BE and of apparent salicylates in the urine being tested. 
<0.01).
this is exactly the case, each individual laboratory should determine the impact, if any, of this salicylateinduced phenomenon on their own drug screening protocol.
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